Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00175
|
|||||
| Drug Name |
Zalcitabine
|
|||||
| Synonyms |
1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine; 2',3'-DIDEOXYCYTIDINE; 2',3'-Dideoxycytidine & Interferon-alpha; 2',3'-Dideoxycytidine & Nanoparticles (from human serum albumin or polyhexylcyanoacrylate); 2',3'-Dideoxycytidine & sCD4(soluble recombinant protein); 2,3-dideoxycytidine; 3'-Azido-3'-deoxythymidine/2',3'-Dideoxycytidine; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; Beta-D-2',3'-Dideoxycytidine; Beta-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor; Beta-D-DDC; Cytidine, 2',3'-dideoxy & Interferon alpha; Cytidine, 2',3'-dideoxy-& Colony-stimulating factor; D 5782; DDC (DDC); DS-4152 & ddC; DdC; DdC & GM-CSF; DdC & IFN-alpha; DdC & Interferon alpha; DdC & NP (from PHCA or HSA); DdC & sCD4; DdC (Antiviral); DdCyd; Dideoxycytidine; HIVID; Hivid (TN); Hivid(TM); Hivid, Dideoxycytidine, NSC 606170, Zalcitabine; Interferon AD + ddC; KS-1130; Lecithinized superoxide dismutase & .beta.-D-2',3'-Dideoxycytidine; PC-SOD & ddC; Ro 24-2027/000; Ro-24-2027/000; SRI-7707; Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxycytidine; Zalcitabine (JAN/USP/INN); Zalcitabine [USAN:INN:BAN]; Zalcitibine
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Human immunodeficiency virus infection [ICD11: 1C62.Z] | Approved | [1] | |||
| Therapeutic Class |
Anti-HIV Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C9H13N3O3
|
|||||
| Canonical SMILES |
C1CC(OC1CO)N2C=CC(=NC2=O)N
|
|||||
| InChI |
InChI=1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1
|
|||||
| InChIKey |
WREGKURFCTUGRC-POYBYMJQSA-N
|
|||||
| CAS Number |
CAS 7481-89-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 211.22 | Topological Polar Surface Area | 88.2 | ||
| Heavy Atom Count | 15 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 3 | |||
| XLogP |
-1.3
|
|||||
| PubChem CID | ||||||
| PubChem SID |
11467065
, 11468185
, 11486840
, 11504751
, 11528334
, 11532889
, 14797711
, 15171927
, 17389522
, 17404923
, 22391526
, 22431601
, 24278377
, 24862834
, 25819962
, 26719633
, 26752752
, 26752753
, 29291163
, 3259589
, 46386814
, 46488030
, 46507879
, 47216920
, 47216921
, 47589142
, 48185139
, 48334652
, 48416706
, 48422195
, 48422429
, 48423540
, 48424478
, 49681781
, 49693297
, 49699414
, 49734166
, 50105404
, 50105405
, 595891
, 596441
, 596607
, 596679
, 601537
, 602107
, 7847478
, 7980904
, 8167576
, 878108
, 9416
|
|||||
| ChEBI ID |
CHEBI:10101
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP8 | Transporter Info | Multidrug resistance-associated protein 8 | Substrate | [2] | |
| OAT1 | Transporter Info | Organic anion transporter 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Zalcitabine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine. J Biol Chem. 2003 Aug 8;278(32):29509-14. | |||||
| 3 | Interaction of zalcitabine with human organic anion transporter 1. Pharmazie. 2006 May;61(5):491-2. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.